Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 12-Oct-23 4:00 PM View:  | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Oct-23 | Planned Option Sale | 785 | $2.02 | $1,585.70 | (2%) 36.69K to 35.9K | |
| 12-Oct-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Oct-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 7% 34.39K to 36.69K | |
| 13-Sep-23 4:06 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Sep-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 7% 32.81K to 35.1K | |
| 13-Sep-23 4:06 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Sep-23 | Planned Option Sale | 711 | $2.20 | $1,564.20 | (2%) 35.1K to 34.39K | |
| 14-Aug-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Aug-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 7% 31.2K to 33.5K | |
| 14-Aug-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Aug-23 | Planned Option Sale | 682 | $2.36 | $1,609.52 | (2%) 33.5K to 32.81K | |
| 12-Jul-23 4:29 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Jul-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 8% 29.6K to 31.89K | |
| 12-Jul-23 4:29 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Jul-23 | Planned Option Sale | 687 | $2.34 | $1,607.58 | (2%) 31.89K to 31.2K | |
| 21-Jun-23 4:00 PM View: | Simon Farrell Chief Commercial Officer | Trevi Therapeutics, Inc. (TRVI) | 20-Jun-23 | Option Exercise | 6,250 | $0.51 | $3,193.75 | 16% 39.4K to 45.65K | |
| 14-Jun-23 4:28 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 12-Jun-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 8% 27.92K to 30.21K | |
| 14-Jun-23 4:28 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 12-Jun-23 | Planned Option Sale | 610 | $2.64 | $1,610.40 | (2%) 30.21K to 29.6K | |
| 15-May-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-May-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 9% 26.19K to 28.48K | |
| 15-May-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-May-23 | Planned Option Sale | 562 | $2.89 | $1,624.18 | (2%) 28.48K to 27.92K | |
| 12-Apr-23 5:02 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 9% 24.74K to 27.03K | |
| 12-Apr-23 5:02 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-23 | Planned Option Sale | 840 | $1.84 | $1,544.76 | (3%) 27.03K to 26.19K | |
| 15-Mar-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Mar-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 10% 23.34K to 25.63K | |
| 15-Mar-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Mar-23 | Planned Option Sale | 892 | $1.75 | $1,563.85 | (3%) 25.63K to 24.74K | |
| 08-Mar-23 4:00 PM View: | Simon Farrell Chief Commercial Officer | Trevi Therapeutics, Inc. (TRVI) | 07-Mar-23 | Option Exercise | 18,750 | $0.51 | $9,581.25 | 91% 20.65K to 39.4K | |
| 15-Feb-23 4:01 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Feb-23 | Option Exercise | 27,500 | $0.51 | $14,052.50 | 638% 4.31K to 31.81K | |
| 15-Feb-23 4:01 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Feb-23 | Planned Option Sale | 8,474 | $2.45 | $20,761.30 | (27%) 31.81K to 23.34K | |
| 06-Jul-22 5:00 PM View: | Tpg Gp A, LLC | Trevi Therapeutics, Inc. (TRVI) | 05-Jul-22 | Sale | 63,569 | $3.11 | $197,827.00 | (2%) 3.89M to 3.82M | |
| 06-Jul-22 5:00 PM View: | Tpg Gp A, LLC | Trevi Therapeutics, Inc. (TRVI) | 01-Jul-22 | Private Sale | 436,431 | $2.86 | $1,246,190.00 | (10%) 4.32M to 3.89M | |
| 01-Jul-22 4:10 PM View: | Tpg Gp A, LLC 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 30-Jun-22 | Sale | 429,838 | $2.77 | $1,191,900.00 | (9%) 4.75M to 4.32M | |
| 01-Jul-22 4:10 PM View: | Tpg Gp A, LLC 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 29-Jun-22 | Private Sale | 46,128 | $2.74 | $126,303.00 | (< 1%) 4.8M to 4.75M | |
| 04-May-22 5:17 PM View: | Tpg Gp A, LLC 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 02-May-22 | Private Sale | 600 | $2.70 | $1,620.00 | (< 1%) 4.8M to 4.8M | |
| 02-May-22 5:04 PM View: | Tpg Gp A, LLC 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 29-Apr-22 | Sale | 16,163 | $2.75 | $44,385.20 | (< 1%) 4.82M to 4.8M | |
| 02-May-22 5:04 PM View: | Tpg Gp A, LLC 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 28-Apr-22 | Private Sale | 7,271 | $2.77 | $20,139.90 | (< 1%) 4.82M to 4.82M | |
| 13-Apr-22 5:10 PM View: | Behbahani Ali 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:13 PM View: | Chang Carmen 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:18 PM View: | Florence Anthony A. Jr. 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:29 PM View: | Walker Paul Edward 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:00 PM View: | New Enterprise Associates 1... 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase | 2,631,580 | $1.90 | $5,000,000.00 | 34% 7.79M to 10.42M | |
| 13-Apr-22 5:21 PM View: | Makhzoumi Mohamad 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:32 PM View: | Mathers Edward T Director | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Grant | 948,948 | $1.90 | $1,803,000.00 | 100% 0 to 948.95K | |
| 13-Apr-22 5:24 PM View: | Sandell Scott D 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:26 PM View: | Sonsini Peter W. 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 3,580,530 | $1.90 | $6,803,000.00 | 46% 7.79M to 11.37M | |
| 13-Apr-22 5:04 PM View: | Baskett Forest 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-22 | Purchase Duplicate | 2,631,580 | $1.90 | $5,000,000.00 | 34% 7.79M to 10.42M | |
| 19-Oct-21 9:15 PM View: | Sandell Scott D 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:15 PM View: | Sonsini Peter W. 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:10 PM View: | Baskett Forest 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:11 PM View: | Behbahani Ali 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:12 PM View: | Chang Carmen 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:13 PM View: | Florence Anthony A. Jr. 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:17 PM View: | Walker Paul Edward 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:09 PM View: | New Enterprise Associates 1... 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 19-Oct-21 9:14 PM View: | Makhzoumi Mohamad 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 18-Oct-21 | Purchase Duplicate | 1,851,850 | -- | -- | 31% 5.94M to 7.79M | |
| 13-Apr-20 9:01 PM View: | Sandell Scott D 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 03-Apr-20 | Market Sale Duplicate | 564 | $2.66 | $1,500.24 | (< 1%) 5.94M to 5.94M | 54% |
| 13-Apr-20 9:02 PM View: | Sonsini Peter W. 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 03-Apr-20 | Market Sale Duplicate | 564 | $2.66 | $1,500.24 | (< 1%) 5.94M to 5.94M | 54% |
| 13-Apr-20 9:00 PM View: | Makower Joshua 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 03-Apr-20 | Exercise (in-the money or at-the-money) Duplicate | 1,500,000 | $0.00 | $1,500.00 | 34% 4.44M to 5.94M | |
| 13-Apr-20 9:23 PM View: | Baskett Forest 10% Owner | Trevi Therapeutics, Inc. (TRVI) | 03-Apr-20 | Market Sale Duplicate | 564 | $2.66 | $1,500.24 | (< 1%) 5.94M to 5.94M | 54% |
